Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Refnot + chemotherapy
- Development stage
- Unknown
- Lead developer
- Refnot-Pharm
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Refnot is a recombinant fusion protein consisting of tumor necrosis factor-alpha (TNF-α) and thymosin alpha-1 (Tα1), joined by an Ile-Asp-Met tripeptide linker. Developed by Refnot-Pharm Ltd, the drug is designed to leverage the potent antitumor cytotoxic activity of TNF-α while utilizing the immunomodulatory properties of thymosin alpha-1 to enhance T-cell function and reduce the systemic toxicity typically associated with native TNF. This hybrid biologic exhibits a toxic potential more than 100 times lower than recombinant TNF alone, allowing for safer therapeutic administration. In clinical settings, Refnot is evaluated both as a monotherapy and in combination with various chemotherapy regimens for the treatment of disseminated solid tumors, including melanoma, breast cancer, and gastrointestinal malignancies.
- Brand names
- Refnot
- Other names
- Tumor necrosis factor-thymosin alfa 1 recombinantTNF-thymosin alpha 1
02
Targets
TNFR2 (Tumor necrosis factor receptor superfamily member 1B)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)
Beyond the preview
Go deeper on Refnot + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Refnot + chemotherapy.